'Preimplantation Genetic Diagnosis 2018: Current Practice and Beyond', 9-10 November 2018
Page URL: https://www.bionews.org.uk/page_96233

Broad Institute responds to Berkeley CRISPR patent appeal

30 October 2017
Appeared in BioNews 924

The Broad Institute has filed arguments ahead of the upcoming CRISPR patent appeal hearing.

This marks the latest development in ongoing dispute over the US patent for CRISPR/Cas9 between the University of California at Berkeley (UC), and the University of Vienna and Professor Emmanuelle Charpentier, against the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, regarding who has the right to a patent on the eukaryotic application of CRISPR/Cas9 technology.

In July, the University of California appealed the decision of the US Patent Trial and Appeal Board (PTAB) over the use of CRISPR in eukaryotic cells. The appeal will be heard in the US Court of Appeals for the Federal Circuit early in 2018.

The UC brief, issued on 25 July 2017, stated that the PTAB 'ignored key evidence' and 'made multiple errors' when assessing whether CRISPR/Cas9 genome editing in eukaryotes was an obvious extension of the UC invention.

The Broad brief refutes these claims, arguing that PTAB's decision was lawful and based on factual evidence, and that the decision should stand.

In 2012, researchers at UC - including Professor Jennifer Doudna and Professor Emmanuelle Charpentier – first filed a patent for their discovery of CRISPR/Cas9 and its ability to edit purified DNA in vitroSubsequently, researchers at the Broad Institute used CRISPR/Cas9 to edit the genome of eukaryotic cells, and were granted a patent based on this use.

UC claims that Professors Doudna and Charpentier's work provided obvious evidence that genome editing could be made to work in living mammalian cells. Thus they contend that the patent held by the Broad/MIT for this application is not novel.

Kevin Noonan, a partner at the law firm McDonnell Boehnen Hulbert & Berghoff in Chicago, Illinois, commented that the court can usually be expected to uphold the patent office's decisions. He said:  'For Berkeley to prevail, the Federal Circuit is going to have to say, "Yeah, the board got it wrong" …I think it’s unlikely that they’ll do that.'

SOURCES & REFERENCES
Bitter CRISPR patent war intensifies
Nature News |  26 October 2017
Broad Institute Responds to UC Berkeley Appeal of CRISPR-Cas9 Patent Interference Decision
GenomeWeb |  26 October 2017
Broad Institute takes three lines of attack in CRISPR appeal filing
Life Sciences Intellectual Property Review |  26 October 2017
FOR JOURNALISTS: STATEMENT AND BACKGROUND ON THE CRISPR PATENT PROCESS
Broad Institute |  25 October 2017
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
7 May 2018 - by Sam Sherratt 
After three years of intense legal battles over the patent rights to CRISPR genome editing technology, lawyers for the University of California Berkeley and the Broad Institute in Cambridge, Massachusetts faced off in court again...
19 February 2018 - by Rikita Patel 
Researchers have found a new use for CRISPR, adapting the system to detect viral infections with high accuracy, a new study finds...
21 August 2017 - by Annabel Slater 
I'm glad to see a scientist engaging so strongly in public debate about the use of technology, rather than speculating on the sidelines...
31 July 2017 - by Dr Rachel Brown 
The University of California has moved to appeal a decision of the US Patent Trial and Appeal Board over the use of CRISPR in eukaryotic cells...
2 May 2017 - by Brian Nolan 
The European Patent Office and the United States Patent and Trademark Office have been thrust into a dispute pitting the University of California, Berkeley and the University of Vienna against the Broad Institute of MIT and Harvard University. Scientists and inventors have been watching the decisions of the EPO and USPTO because these decisions may leave one of these entities with a patent portfolio worth billions of dollars...
20 February 2017 - by Ryan Ross 
The US Patent and Trademark Office has upheld the right of the Broad Institute of MIT and Harvard to the genome-editing tool CRISPR/Cas9...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.